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Diabetic Ketoacidosis: Pathophysiology and Treatment
Diabetic ketoacidosis (DKA), also known as diabetic acidosis or diabetic coma, is a
severe complication of diabetes mellitus (DM; Michel, 2011). More commonly seen in patients
with type 1 diabetes (T1D), DKA results when lipid breakdown generates a surplus of acidic
ketone bodies (Guven, Matfin, & Kuenzi, 2009). According to Dods (2013), DKA can be
defined as a condition with “blood glucose greater than 250 mg/dL, blood bicarbonate less than
15 mEq/L, pH less than 7.35, ketonemia, and increased anion gap” (p. 266). The
pathophysiology of DKA in patients with T1D will first be addressed, followed by a discussion
of proper emergency treatment for this life-threatening condition.
The three main abnormalities of DKA patients include hyperglycemia, ketosis, and
metabolic acidosis (Guven et al., 2009). An episode of DKA is precipitated by insulin deficiency
with hyperglycemia. Insulin deficiency may develop in a patient following illness or infection,
an insufficient insulin dose, ignorance of the condition of T1D, neglect of the medication
regimen, and defective self-health maintenance (Michel, 2011). When insulin fails to provide
adequate glucose, the cells tap into the fat stores for fuel (Petit & Adamee, 2011). It is the acidic
products of fat metabolism that account for the acidosis. Normally, pancreatic beta cells release a
bolus of insulin in response to rising blood glucose levels; however, in T1D the beta cells are
destroyed through autoimmune process and the result is an absolute insulin deficiency (Michel,
2011). Without insulin secretion, hyperglycemia persists, and the cells starve for energy.
The energy-hungry cells stimulate adipose tissue lipolysis, releasing free fatty acids into
the blood stream. Increased breakdown of adipose tissue into glycerol and fatty acids is related to
the increased availability of tissue lipase, an enzyme that is suppressed by insulin. Low insulin
levels also correlate with low lipoprotein lipase activity, which leads to lipolysis. Free fatty acids
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circulate until they reach the liver and are transported into mitochondria for oxidation by
carnitine palmitoyl transferase (CPT1). It is pertinent to note that CPT1 is usually inhibited when
insulin levels are normal. Acetyl Coenzyme A (CoA) is an enzyme that responds to the presence
of insulin by catalyzing the transformation of acetyl CoA into malonyl CoA. Malonyl CoA is the
molecule that inhibits CPT1 and, therefore, fatty acid oxidation. When CPT1 is unhindered by
insulin, it shuttles fatty acids into the hepatic mitochondria where they undergo oxidation and
form ketone bodies, namely, beta-hydroxybutyrate, acetoacetate, and acetone (Casteels &
Mathieu, 2003; Marieb, 2004).
Ketones can be used as an alternate fuel source by cells lacking mitochondria and by
brain cells, but in a state of insulin deficiency ketone utilization by the peripheral tissues is
diminished (Harvey, 2010; Casteels & Mathieu, 2003). An overproduction and an underutilization of ketoacids results in ketosis (Casteels & Mathieu, 2003). Bicarbonate ions buffer the
increased hydrogen ions by forming water and carbon dioxide; nevertheless, as ketosis
progresses bicarbonate cannot keep up, and a metabolic acidosis ensues (Casteels & Mathieu,
2003). In a state of ketosis, beta-hydroxybutyrate and acetoacetate are eliminated by the kidneys
along with their counter ions, potassium, and sodium (Dods, 2013). This ketonuria contributes to
the acidosis by causing the hydrogen ion concentration to rise (2013).
Besides increased lipolysis, the body responds to the glucose-hungry cells by increasing
serum glucose levels even though hypoglycemia is not the problem (Beard, 2011).
Hyperglycemia is further exacerbated by the release of counter regulatory hormones (Casteels &
Mathieu, 2003). Low insulin levels cause the secretion of hormones that increase hepatic
formation of new glucose molecules and hepatic breakdown of stored glycogen into glucose
molecules (Koul, 2009). Hormones such as glucagon, catecholamines, cortisol, and growth

Published by Scholars Crossing, 2015

3

The Kabod, Vol. 2, Iss. 1 [2015], Art. 3
DIABETIC KETOACIDOSIS

4

hormone are released; they not only increase the blood glucose but also have an antagonistic
effect toward insulin (Beard, 2011). Glucagon is a hormone secreted by the alpha cells of the
islets of Langerhans that increases proteolysis, transports the resulting amino acids into liver
cells, and converts these amino acids into glucose precursors during the process of
gluconeogenesis (Guven et al., 2009). Insulin promotes the active transport of amino acids into
the cells and prevents protein breakdown (Guven et al., 2009). Catacholamines respond to stress
by stimulating lypolysis in adipose tissue, decreasing insulin secretion, and increasing hepatic
glycogenolysis and gluconeogenesis (Michal, 2012). Corticotropin-releasing hormone is released
from the hypothalamus and stimulates the pituitary gland to synthesize and secrete
adrenocorticotropic hormone (ACTH), which induces the adrenal cortex to secrete cortisol into
the blood (Michal, 2012). Cortisol acts as an antagonist to insulin by promoting gene
transcription of catabolic enzymes in extrahepatic cells (Michal, 2010). Cortisol also stimulates
gluconeogenesis in the liver (Michal, 2012). Growth hormone (GH) mobilizes fatty acids to be
used as fuel and inhibits glucose uptake by insulin in the peripheral cells (Guven et al., 2009).
With these in place, GH increases protein synthesis and sustains hyperglycemia (Guven et al.,
2009).
Patients with T1D exhibit polyuria and polydipsia. As the blood becomes increasingly
overloaded with glucose, the kidneys’ reabsorbing threshold is surpassed and glucose is excreted
in the urine. Glucose is an osmotically active particle and pulls water out of the filtrate and into
the urine. Polydipsia occurs because hyperglycemia causes fluid shifts in the cells resulting in
dehydration. T1D patients may also experience polyphagia because their cells are starving for
energy and their body’s stores of carbohydrates, fats, and proteins are depleted. Because of this
use of the body’s stores of fat and protein and the loss of fluid, patients with T1D often
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experience weight loss. Polyphagia is not present in all T1D patients because of the epigastric
pain and vomiting that often accompanies their acidotic state (Koul, 2009; Guven et al., 2009).
The osmotic diuresis that results in the patient’s experience of polyuria also has dramatic
effects on electrolyte levels. Sodium, potassium, phosphate, and magnesium are lost in the urine
which predisposes the DKA patient to dehydration and imbalanced electrolyte levels (Guven et
al., 2009). Ketonemia leads to ketonuria; potassium and sodium are excreted with ketones as
their counter ions (Dods, 2013). Despite the loss of potassium in the urine, potassium levels often
stay normal due to potassium shifts from the intracellular compartment to the extracellular
compartment (Grinslade & Buck, 1999). Circulating hydrogen ions move into the cells in an
attempt to correct the acidosis (Casteels & Mathieu, 2003). Within the cells, the hydrogen
cations are buffered and potassium cations leave the cell in order to maintain intracellular
electrical balance (Casteels & Mathieu, 2003). Extracellular potassium may also be increased by
proteolysis (Grinslade & Buck, 1999). Although the serum levels of potassium appear normal or
even high, the total body potassium level is depleted in DKA patients (Casteels & Mathieu,
2003).
A patient with DKA may take rapid, deep breaths called Kussmaul respirations in an
attempt to blow off carbon dioxide to normalize the blood pH. According to Nattrass (2002),
“Spontaneous decarboxylation of acetoacetate allows excretion of acetone through the lungs” (p.
52), giving the breath a fruity odor. Tachycardia and hypotension may also manifest due to
decreased blood volume, which will be further depleted by vomiting (Guven et al., 2009; Koul,
2009).
Proper treatment of DKA is focused on restoring blood volume, enhancing tissue
perfusion, correcting hyperglycemia and acidosis, and normalizing electrolyte levels (Guven,
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2009). Due to the emergent and life-threatening nature of DKA, the patient must be treated
promptly. Intravenous (IV) access should be initiated to administer fluid and electrolyte
replacement. Fluid replacement is necessary for expanding the blood volume so that the tissues
can be perfused and receive insulin (Koul, 2009). Restored blood volume also diminishes the
release of counter regulatory hormones especially catacholamines and cortisol (Casteels &
Mathieu, 2003). When serum sodium is low, a solution of 0.9% NaCl should be infused at a rate
of one liter per hour or at a rate that achieves a restored urine output of 30-60 mL/hr. and a
stabilized blood pressure (Michel, 2011; Koul, 2009). If the sodium level is within or above the
normal limits, 0.45% NaCl is used (Koul, 2009).
If fluid replacement dilutes the serum sodium concentration, cerebral edema may ensue
especially in pediatric patients. DKA patients are often dehydrated before treatment because of
the high concentration of osmotically active substances, such as glucose, in the extracellular
fluid. According to Koul (2009), “Persistent glucose-induced hypertonicity is implicated in
causing neural cells to produce osmotically active idiogenic molecules” (p. 140). Neural cells
accumulate these molecules during dehydration to protect the brain from becoming too volume
depleted. When IV fluids resolve the high serum osmolality, the brain cells draw water out of the
extracellular fluid resulting in cerebral swelling. Monitoring for the manifestations of Cushing’s
triad is useful for assessing increased intracranial pressure, and unequal pupil dilation may
indicated herniation. Neurological assessments are key to identifying cerebral edema, and rapid
intervention involves the administration of mannitol and an alteration of the IV fluid rate. If
mannitol is not available, a hypertonic solution of three percent saline may be administered with
careful observance of hypernatremia, hyperosmolality, and central pontine myelinolysis (Koul,
2009).
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Because of the detrimental effects of cerebral edema, fluid replacement therapy should
progress slowly. Since insulin draws potassium and glucose into the intracellular compartment,
potassium levels should be ascertained before the administration of insulin to prevent
hypokalemia. If the patient’s potassium level is low before fluid administration then potassium
should be given along with fluid replacement. The potassium level should be restored to 3.5 to
5.0 mg/dL to prevent cardiac dysrhythmias. Once the blood volume has been replenished and the
potassium level is above 3.5 mg/dL, administration of insulin should begin (Michel, 2011).
Insulin corrects hyperglycemia and hyperketonemia; a continuous IV infusion is initiated at a
rate of 0.1 units/kg/hr. (Michel, 2011). The potassium level should be intensely monitored during
insulin administration. Potassium should be added to the IV infusion if the level falls below 3.5
mg/dL (Guven et al., 2009). The blood sugar should also be monitored during insulin therapy. If
glucose levels reach 250 mg/dL a solution of five percent dextrose is administered to prevent
hypoglycemia (Michel, 2011). Insulin should be infused slowly because rapidly lowering serum
glucose levels may also precipitate cerebral swelling (Michel, 2011). According to Guven et al.
(2009), severe acidosis exerts inhibitory effects on insulin. The patient should be started on a
loading dose of regular insulin and then continuously infused with low doses of insulin (Guven
et al., 2009).
DKA therapy must be actively guided by the fluid and electrolyte levels that the patient
manifests. Koul (2009) encourages having two qualified medical personnel separately
calculating fluid management to avoid calculation errors. Emergency supplies such as mannitol
and dextrose solution should be readily available (Koul, 2009). Prevention of DKA is achieved
through adequate patient teaching on the insulin regimen and early diagnosis of T1D in patients
who may be at risk.
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